NeoGenomics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $509.00K, a 3081.25% increase year-over-year.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $764.00K, a 1217.24% increase year-over-year.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $16.00K, a 99.31% decline year-over-year.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $58.00K, a 43.14% decline year-over-year.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $303.00K, a 91.66% decline from fiscal 2024.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $3.63M, a 20.59% increase from fiscal 2023.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $3.01M, a 70.99% decline from fiscal 2022.
- NeoGenomics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $10.38M, a 24.13% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $509.00K 10-Q · filed 2026-07-28 | |
| 2026-03-31 | $764.00K 10-Q · filed 2026-07-28 | |
| 2025-12-31 | $303.00K 10-K · filed 2026-02-17 | |
| 2025-06-30 | $16.00K 10-Q · filed 2026-07-28 | |
| 2025-03-31 | $58.00K 10-Q · filed 2026-07-28 | |
| 2024-12-31 | $3.63M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $886.00K 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $2.32M 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $102.00K 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $3.01M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $1.03M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $610.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $751.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $10.38M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $1.96M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $743.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $6.48M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $13.68M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $3.37M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $4.43M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $2.24M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $18.27M 10-K · filed 2023-02-24 | |
| 2020-09-30 | $4.85M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $2.01M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $2.90M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $9.97M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $2.17M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $3.37M 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $3.89M 10-Q · filed 2020-10-29 | |
| 2018-12-31 | $8.60M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $979.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $4.92M 10-Q · filed 2019-11-13 | |
| 2018-03-31 | $216.00K 10-Q · filed 2019-11-13 | |
| 2017-12-31 | $1.96M 10-K · filed 2020-02-28 | |
| 2016-12-31 | $3.30M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $714.00K 10-K · filed 2018-03-13 | |
| 2014-12-31 | $1.81M 10-K · filed 2017-03-14 | |
| 2013-12-31 | $372.00K 10-K · filed 2016-04-18 | |
| 2012-12-31 | $198.00K 10-K · filed 2015-03-03 | |
| 2011-12-31 | $367.00K 10-K · filed 2014-02-24 | |
| 2010-12-31 | $68.00K 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |